Takeaways: Jupiter’s ALA-002 deal gives it a high-upside, FDA-designated NCE asset in the emerging U.S. psychedelic therapeutics space, expanding the company from one CNS program to two clinical...
Browsing Tag: CNS pipeline
Takeaways: Jupiter’s ALA-002 deal gives it a high-upside, FDA-designated NCE asset in the emerging U.S. psychedelic therapeutics space, expanding the company from one CNS program to two clinical...